|
BRPI0707427A2
(pt)
*
|
2006-02-03 |
2011-05-03 |
Lilly Co Eli |
composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar dislipidemia, aterosclerose, e diabetes e complicações da mesma, para elevar os nìveis plásmicos de hdl, e para diminuir triglicerìdeos plásmicos, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
|
|
CL2007003035A1
(es)
*
|
2006-10-24 |
2008-05-16 |
Smithkline Beechman Corp |
Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
|
|
MX2010005753A
(es)
|
2007-12-04 |
2010-06-15 |
Hoffmann La Roche |
Derivados de isoxazolo-pirazina.
|
|
US7902201B2
(en)
|
2007-12-04 |
2011-03-08 |
Hoffmann-La Roche Inc. |
Isoxazolo-pyrazine derivatives
|
|
US7943619B2
(en)
|
2007-12-04 |
2011-05-17 |
Hoffmann-La Roche Inc. |
Isoxazolo-pyridazine derivatives
|
|
EP2367554A4
(en)
*
|
2008-11-26 |
2020-03-25 |
Satiogen Pharmaceuticals, Inc. |
Bile acid reflux inhibitor for the treatment of obesity and diabetes
|
|
TW201033201A
(en)
|
2009-02-19 |
2010-09-16 |
Hoffmann La Roche |
Isoxazole-isoxazole and isoxazole-isothiazole derivatives
|
|
US8389550B2
(en)
|
2009-02-25 |
2013-03-05 |
Hoffmann-La Roche Inc. |
Isoxazoles / O-pyridines with ethyl and ethenyl linker
|
|
US8222246B2
(en)
|
2009-04-02 |
2012-07-17 |
Hoffmann-La Roche Inc. |
Substituted isoxazoles
|
|
US20100280019A1
(en)
|
2009-04-30 |
2010-11-04 |
Roland Jakob-Roetne |
Isoxazoles
|
|
SG175867A1
(en)
|
2009-05-05 |
2011-12-29 |
Hoffmann La Roche |
Isoxazole-pyridine derivatives
|
|
EP2427455B1
(en)
|
2009-05-05 |
2020-01-15 |
F.Hoffmann-La Roche Ag |
Isoxazole-pyrazole derivatives
|
|
BRPI1011729A2
(pt)
|
2009-05-05 |
2016-03-15 |
Hoffmann La Roche |
derivados de isoxazol-tiazol como um receptor inverso gaba a agonista para uso no tratamento de distúrbios cognitivos
|
|
AU2010244545A1
(en)
|
2009-05-05 |
2011-10-13 |
F. Hoffmann-La Roche Ag |
Isoxazole-pyridazine derivatives
|
|
AU2010244555A1
(en)
|
2009-05-07 |
2011-11-03 |
F. Hoffmann-La Roche Ag |
Isoxazole-pyridine derivatives as GABA modulators
|
|
EP2289883A1
(en)
|
2009-08-19 |
2011-03-02 |
Phenex Pharmaceuticals AG |
Novel FXR (NR1H4) binding and activity modulating compounds
|
|
EP4137137A1
(en)
|
2010-05-26 |
2023-02-22 |
Satiogen Pharmaceuticals, Inc. |
Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
|
|
EP2545964A1
(en)
|
2011-07-13 |
2013-01-16 |
Phenex Pharmaceuticals AG |
Novel FXR (NR1H4) binding and activity modulating compounds
|
|
WO2013037482A1
(en)
|
2011-09-15 |
2013-03-21 |
Phenex Pharmaceuticals Ag |
Farnesoid x receptor agonists for cancer treatment and prevention
|
|
US8785435B2
(en)
|
2011-10-20 |
2014-07-22 |
Hoffmann-La Roche Inc. |
Solid forms
|
|
US20140323412A1
(en)
|
2011-10-28 |
2014-10-30 |
Lumena Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
|
|
SG10201909122QA
(en)
|
2011-10-28 |
2019-11-28 |
Lumena Pharmaceuticals Inc |
Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
|
|
CA2907230A1
(en)
|
2013-03-15 |
2014-09-18 |
Lumena Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
|
|
CA2907214A1
(en)
|
2013-03-15 |
2014-09-18 |
Lumena Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease
|
|
JP6366721B2
(ja)
|
2013-09-11 |
2018-08-01 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Ｂ型肝炎ウイルス感染症を処置するための方法及び医薬組成物
|
|
EP3878848A1
(en)
|
2013-11-22 |
2021-09-15 |
Sabre Therapeutics LLC |
Autotaxin inhibiting indole compounds
|
|
CN104045635A
(zh)
*
|
2014-06-23 |
2014-09-17 |
华东理工大学 |
3,4,5-三取代异恶唑类化合物及其用途
|
|
EP3006939A1
(en)
|
2014-10-06 |
2016-04-13 |
Gilead Sciences, Inc. |
Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation
|
|
US10208081B2
(en)
|
2014-11-26 |
2019-02-19 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
|
|
EP3034501A1
(en)
|
2014-12-17 |
2016-06-22 |
Gilead Sciences, Inc. |
Hydroxy containing FXR (NR1H4) modulating compounds
|
|
EP3034499A1
(en)
|
2014-12-17 |
2016-06-22 |
Gilead Sciences, Inc. |
Novel FXR (NR1H4) modulating compounds
|
|
TWI698430B
(zh)
|
2015-02-13 |
2020-07-11 |
南北兄弟藥業投資有限公司 |
三環化合物及其在藥物中的應用
|
|
SI3277286T1
(sl)
|
2015-03-31 |
2021-09-30 |
Enanta Pharmaceuticals, Inc. |
Derivati žolčne kisline kot antagonisti FXR/TGR5 in metode za njihovo uporabo
|
|
CA2981507A1
(en)
*
|
2015-04-07 |
2016-10-13 |
Intercept Pharmaceuticals, Inc. |
Pharmaceutical compositions for combination therapy
|
|
EP4026549A1
(en)
*
|
2015-05-27 |
2022-07-13 |
Sabre Therapeutics LLC |
Autotaxin inhibitors and uses thereof
|
|
WO2017133521A1
(zh)
*
|
2016-02-01 |
2017-08-10 |
山东轩竹医药科技有限公司 |
Fxr受体激动剂
|
|
WO2017189652A1
(en)
|
2016-04-26 |
2017-11-02 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
US10080742B2
(en)
|
2016-04-26 |
2018-09-25 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as FXR agonists and methods of use thereof
|
|
WO2017189663A1
(en)
*
|
2016-04-26 |
2017-11-02 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
US10144729B2
(en)
|
2016-05-18 |
2018-12-04 |
Enanta Pharmaceuticals, Inc. |
Isoxazole analogs as FXR agonists and methods of use thereof
|
|
US10138228B2
(en)
|
2016-05-18 |
2018-11-27 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as FXR agonists and methods of use therof
|
|
US10149835B2
(en)
|
2016-05-18 |
2018-12-11 |
Elmore Patent Law Group, P.C. |
Isoxazole derivatives as FXR agonists and methods of use thereof
|
|
KR20190040936A
(ko)
*
|
2016-05-25 |
2019-04-19 |
아카나 테라퓨틱스, 엘티디. |
파르네소이드 x 수용체 (fxr) 조정제와의 조합 요법
|
|
US10772813B2
(en)
|
2016-06-03 |
2020-09-15 |
Colradel, LLC |
Compositions and methods of administering a colchicine based topical composition for the prevention of radiation fibrosis
|
|
ES2921432T3
(es)
|
2016-06-13 |
2022-08-25 |
Gilead Sciences Inc |
Derivados de azetidina como moduladores de FXR (NR1H4)
|
|
CA2968836C
(en)
|
2016-06-13 |
2025-09-02 |
Gilead Sciences, Inc. |
FXR MODULATING COMPOUNDS (NR1H4)
|
|
TW201808283A
(zh)
|
2016-08-05 |
2018-03-16 |
廣東東陽光藥業有限公司 |
含氮三環化合物及其在藥物中的應用
|
|
EP3523298A4
(en)
|
2016-10-04 |
2020-06-24 |
Enanta Pharmaceuticals, Inc. |
ISOXAZOLANALOGA AS FXR AGONISTS AND METHOD FOR USE THEREOF
|
|
US10597391B2
(en)
|
2016-10-26 |
2020-03-24 |
Enanta Pharmaceuticals, Inc. |
Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof
|
|
EP4424364B1
(en)
|
2017-03-28 |
2026-01-21 |
Gilead Sciences, Inc. |
Combinations for use in the treatment of cirrhosis and liver fibrosis
|
|
EP3600293A1
(en)
|
2017-03-30 |
2020-02-05 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
|
|
SI3612520T1
(sl)
|
2017-04-12 |
2022-01-31 |
Il Dong Pharmaceutical Co., Ltd. |
Izoksazolni derivati kot agonisti nuklearnega receptorja in njihove uporabe
|
|
KR102731925B1
(ko)
|
2017-11-01 |
2024-11-18 |
브리스톨-마이어스 스큅 컴퍼니 |
파르네소이드 x 수용체 조정제로서의 멀티시클릭 화합물
|
|
SG11202003827YA
(en)
|
2017-11-01 |
2020-05-28 |
Bristol Myers Squibb Co |
Bridged bicyclic compounds as farnesoid x receptor modulators
|
|
KR102732404B1
(ko)
|
2017-11-01 |
2024-11-19 |
브리스톨-마이어스 스큅 컴퍼니 |
파르네소이드 x 수용체 조정제로서의 알켄 화합물
|
|
KR102731924B1
(ko)
|
2017-11-01 |
2024-11-19 |
브리스톨-마이어스 스큅 컴퍼니 |
파르네소이드 x 수용체 조정제로서의 스피로시클릭 화합물
|
|
CN111630051B
(zh)
*
|
2017-11-01 |
2023-12-26 |
百时美施贵宝公司 |
作为法尼醇x受体调节剂的烯烃螺环化合物
|
|
US10689391B2
(en)
|
2017-12-12 |
2020-06-23 |
Enanta Pharmaceuticals, Inc. |
Isoxazole analogs as FXR agonists and methods of use thereof
|
|
CN110128432B
(zh)
|
2018-02-02 |
2021-03-02 |
广东东阳光药业有限公司 |
含氮三环化合物及其在药物中的应用
|
|
WO2019160813A1
(en)
|
2018-02-14 |
2019-08-22 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
PE20211907A1
(es)
|
2019-01-15 |
2021-09-28 |
Gilead Sciences Inc |
Compuestos moduladores de fxr (nr1h4)
|
|
JP7562546B2
(ja)
|
2019-02-12 |
2024-10-07 |
ミルム ファーマシューティカルズ インコーポレイテッド |
胆汁うっ滞性肝疾患を有する小児対象の成長を増加させる方法
|
|
EP3924337A1
(en)
|
2019-02-15 |
2021-12-22 |
Bristol-Myers Squibb Company |
Substituted bicyclic compounds as farnesoid x receptor modulators
|
|
JP7449300B2
(ja)
|
2019-02-15 |
2024-03-13 |
ブリストル－マイヤーズ スクイブ カンパニー |
ファルネソイドｘ受容体モジュレータとして有用な置換アミド化合物
|
|
AR118050A1
(es)
|
2019-02-15 |
2021-09-15 |
Bristol Myers Squibb Co |
Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
|
|
EP3924333A1
(en)
|
2019-02-15 |
2021-12-22 |
Bristol-Myers Squibb Company |
Substituted amide compounds useful as farnesoid x receptor modulators
|
|
KR102725082B1
(ko)
|
2019-02-19 |
2024-11-04 |
길리애드 사이언시즈, 인코포레이티드 |
Fxr 효능제의 고체 형태
|
|
US11555032B2
(en)
|
2019-05-13 |
2023-01-17 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as FXR agonists and methods of use thereof
|
|
AU2020312735A1
(en)
|
2019-07-18 |
2021-12-16 |
Enyo Pharma |
Method for decreasing adverse-effects of interferon
|
|
WO2021108974A1
(en)
|
2019-12-03 |
2021-06-10 |
Gannex Pharma Co., Ltd |
Compounds for modulating activity of fxr and uses thereof
|
|
US20230060715A1
(en)
|
2020-01-15 |
2023-03-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of fxr agonists for treating an infection by hepatitis d virus
|
|
US20240100125A1
(en)
|
2021-01-14 |
2024-03-28 |
Enyo Pharma |
Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
|
|
JP2024517181A
(ja)
|
2021-04-28 |
2024-04-19 |
ウエヌイグレックオ・ファーマ |
組合せ治療としてｆｘｒアゴニストを使用するｔｌｒ３アゴニストの効果の強い増強
|